POST Online Media Lite Edition


Bio Blast announces key leadership changes

Staff writer |
Tel Aviv, Israel - February 3, 2015, Tel Aviv, Israel - Bio Blast Pharma Ltd., a clinical-stage biotechnology company, announced that Colin Foster has joined Bio Blast as president and CEO and a member of its board of directors.

Mr. Foster has extensive experience in leading therapeutic, diagnostic, and medical device companies in the United States and internationally, working across the R&D-to-commercial continuum.

He was founder and CEO of iSci Management LLC, a life sciences advisory firm, co-founder and CEO of Optherion, Inc., a venture backed biologics and diagnostics company targeting ultra-orphan diseases of the immune system and age-related macular degeneration, and prior to that, he was the President and CEO of Bayer Pharmaceuticals Corporation USA and Region Head of the North American Pharmaceuticals business of Bayer AG.

Mr. Foster began his post-graduate career with Sandoz Canada Inc. before embarking on an international career with Bayer in Canada, the USA, and Europe. He currently serves as Chairman of Ivenix, Inc., and is a board member of Optherion, iSci Management LLC, and Vista Vocational & Life Skills Center.

Mr. Foster has a B.Sc. in Zoology and Microbiology from the University of Toronto, and an M.B.A. from Western University in Canada. He is also an active Member of The Jackson Laboratory National Council and Jackson Society.


Cellcom Israel chairman Ami Erel to step down
Nano Dimension appoints Miri Naveh to board
Teva says CFO Michael McClellan will step down
MaxQ AI announces Tom Neufelder as chief technology officer
SodaStream appoints Bryan Welsh as general manager of SodaStream USA

What to read next

TeamQuest names Kris Luhrsen as SVP, sales & partner development
Tupperware Brands appoints two group presidents
Fujifilm Manufacturing U.S.A. promoted Todd Croker